Association of quality of life (QOL) with overall survival (OS) in patients (pts) with HR+/HER2-advanced breast cancer (ABC) treated with ribociclib (RIB) plus endocrine therapy (ET) in the MONALEESA-3 (ML-3) and ML-7 trials - Fasching, Peter; Harbeck, N.; Jerusalem, G.; Colleoni, M. A.; Neven, P.; Franke, F.; De Laurentiis, M.; Tripathy, D.; Martin, M.; Babu, G.; Yardley, D.; Wheatley-Price, P.; et al. (ANNALS OF ONCOLOGY, 2021)
CRIS-Team WoS Importer:2021-10-15